\
&
Contact us
\
&
Contact us
Published on | 5 months ago
Programmes Climate, Energy, Mobility MissionsThe mission on climate adaptation wants to direct policy makers, researchers, citizens, businesses etc. towards the general objective of making the EU more climate resilient by 2030. Over the past 3 years significant progress has been made as we learn more and more how to adapt to the climate change. Now the EC has drawn up a first report to analyse how far we have come. You can find all the information here
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has recently published the first amendment to the Digital Europe Main Work Programme 2025-2027, taking into account the most recent political priorities of the Commission. Among the main changes, the programme will now contribute to the landmark AI Gigafactories initiative, set to accelerate the development of cutting... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
